4.8 Article

BRCA2 antagonizes classical and alternative nonhomologous end-joining to prevent gross genomic instability

Journal

NATURE COMMUNICATIONS
Volume 8, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-017-01759-y

Keywords

-

Funding

  1. Key Program of the National Natural Science Foundation of China [31730021]
  2. National Natural Science Funds for Distinguished Young Scholar
  3. National Program for Special Support of Eminent Professionals
  4. National Natural Science Foundation of China [81661128008, 31571397]
  5. National Postdoctoral Program for Innovative Talents [BX201600134]

Ask authors/readers for more resources

BRCA2-deficient cells exhibit gross genomic instability, but the underlying mechanisms are not fully understood. Here we report that inactivation of BRCA2 but not RAD51 destabilizes RPA-coated single-stranded DNA (ssDNA) structures at resected DNA double-strand breaks (DSBs) and greatly enhances the frequency of nuclear fragmentation following cell exposure to DNA damage. Importantly, these BRCA2-associated deficits are fueled by the aberrant activation of classical (c)- and alternative (alt)-nonhomologous end-joining (NHEJ), and rely on the well-defined DNA damage signaling pathway involving the pro-c-NHEJ factor 53BP1 and its downstream effector RIF1. We further show that the 53BP1-RIF1 axis promotes toxic end-joining events via the retention of Artemis at DNA damage sites. Accordingly, loss of 53BP1, RIF1, or Artemis prolongs the stability of RPA-coated DSB intermediates in BRCA2-deficient cells and restores nuclear integrity. We propose that BRCA2 antagonizes 53BP1, RIF1, and Artemis-dependent c-NHEJ and alt-NHEJ to prevent gross genomic instability in a RAD51-independent manner.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Medicine, Research & Experimental

Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis

Yao Qin, Pu Kuang, Ting Liu

Summary: Venetoclax combined with hypomethylating agents or low-dose cytarabine may be an effective and well-tolerated treatment option for untreated AML patients who cannot tolerate intensive chemotherapy. A meta-analysis of four clinical trials showed higher complete remission rates and median overall survival time in this treatment combination, with common adverse events including nausea, diarrhea, and hypokalemia.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Article Cell Biology

Poly(ADP-ribosylation) of P-TEFb by PARP1 disrupts phase separation to inhibit global transcription after DNA damage

Huanyi Fu, Rongdiao Liu, Zixuan Jia, Ran Li, Feifeng Zhu, Wenxuan Zhu, Yangqing Shao, Yiyang Jin, Yuhua Xue, Jun Huang, Kunxin Luo, Xiang Gao, Huasong Lu, Qiang Zhou

Summary: DNA damage leads to transcriptional stalling to prevent mutagenesis and initiate repair signaling. Poly(ADP-ribose) polymerase (PARP1) inhibits Pol II elongation by inactivating the transcription elongation factor P-TEFb, promoting DNA repair and cell survival.

NATURE CELL BIOLOGY (2022)

Article Cell Biology

Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia

Wei Yu, Hang Zhang, Yuncang Yuan, Jie Tang, Xinchuan Chen, Ting Liu, Xudong Zhao

Summary: This study developed a novel CAR structure targeting GRP78, a cell surface protein, to achieve anti-tumor effects against AML cells without harming normal hematopoietic stem cells. These findings provide a promising approach for the therapy of AML.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Article Medicine, General & Internal

Combining metaphase cytogenetics with single nucleotide polymorphism arrays can improve the diagnostic yield and identify prognosis more precisely in myelodysplastic syndromes

Yao Qin, Hang Zhang, Lin Feng, Haichen Wei, Yuling Wu, Chaoran Jiang, Zhihong Xu, Huanling Zhu, Ting Liu

Summary: The combination of metaphase cytogenetics analysis (MC) and single-nucleotide polymorphism arrays (SNP-A) karyotyping can improve the diagnostic yield and provide more precise prognostic stratification in patients with myelodysplastic syndromes (MDS). SNP-A can detect more chromosomal aberrations and copy number neutral loss of heterozygosity (CN-LOH). Factors such as age, bone marrow blasts, CN-LOH, new aberrations, TGA value, and IPSS-R risk score have prognostic significance in MDS.

ANNALS OF MEDICINE (2022)

Article Immunology

Donor peritoneal-derived cells can attenuate graft-versus-host disease after MHC-incompatible bone marrow transplantation in mice

Zhigang Liu, Qiang Zeng, Xinchuan Chen, Chuan He, Fangfang Wang, Ting Liu

Summary: Donor peritoneal-derived cells can attenuate graft-versus-host disease (GVHD) caused by bone marrow transplantation by regulating cytokine levels and immunocyte ratios.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Article Medicine, Research & Experimental

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5

Yan Yang, Yuhan Gao, Jingcao Huang, Zhuang Yang, Hongmei Luo, Fangfang Wang, Juan Xu, Yushan Cui, Hong Ding, Zhimei Lin, Xinyu Zhai, Ying Qu, Li Zhang, Ting Liu, Lingqun Ye, Ting Niu, Yuhuan Zheng

JCI INSIGHT (2022)

Article Hematology

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study

Wei Xu, Keshu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Yu Hu, Wei Zhang, Kaiyang Ding, Jianfeng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jianda Hu, Chunyan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li

Summary: Orelabrutinib demonstrated significant efficacy and safety in patients with refractory or relapsed CLL/SLL, with an overall response rate of 92.5%. The median progression-free survival had not been reached at a 32.3-month median follow-up. Moreover, Orelabrutinib showed promising response in patients with high prognostic risks.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Hematology

Chronic active Epstein-Barr virus infection involving gastrointestinal tract with hemophagocytic lymphohistiocytosis

Kai Shen, Xiao Shuai, Jianjun Li, Jiazhuo Liu, Ting Liu, Ting Niu, Hongbing Ma

Summary: This case series study summarizes the clinical features, treatment, and prognosis of gastrointestinal chronic active EBV infection (CAEBV) with hemophagocytic lymphohistiocytosis (HLH). The study highlights the importance of early recognition and the possibility of salvage therapy combining surgery, novel therapeutic agents, and/or autologous hematopoietic stem cell transplantation (HSCT).

ANNALS OF HEMATOLOGY (2023)

Article Multidisciplinary Sciences

Alternative telomere maintenance mechanism in Alligator sinensis provides insights into aging evolution

Yu-Zu Guo, Yi Zhang, Qing Wang, Jun Yu, Qiu-Hong Wan, Jun Huang, Sheng-Guo Fang

Summary: Alligators are suitable for studying anti-aging molecular mechanisms because they have low adult mortality rates and no significant telomere shortening. Selection analyses have shown that certain genes in alligators have undergone positive selection, and ALT-related genes are expressed at higher levels, which may contribute to anti-aging strategies.

ISCIENCE (2023)

Article Medicine, General & Internal

Severe Microcytic Anemia Caused by Complex Hereditary Spherocytosis and X-Linked Sideroblastic Anemia with Mutations in SPTB and ALAS2 Genes

Jianying Zhou, Hang Zhang, Yao Qin, Ting Liu

Summary: We present a case of severe anemia in a 16-year-old male with complex hereditary spherocytosis (HS) and X-linked sideroblastic anemia (XLSA) caused by mutations in the spectrin beta (SPTB) and 5-aminolevulinic acid synthase (ALAS2) genes. Next-generation sequencing revealed double heterozygous mutations in exon 19 of the SPTB gene (c.3936G > A:p.W1312X) and exon 2 of the ALAS2 gene (c.37A > G:p.K13E). The mutations were confirmed by Sanger sequencing. The mutations in the SPTB and ALAS2 genes contribute to the more severe clinical phenotypes observed in this patient.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Oncology

Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis

Lu Tang, Zhigang Liu, Tao Li, Tian Dong, Qiuhui Wu, Ting Niu, Ting Liu, Jie Ji

Summary: Through investigating 1091 articles, it was found that the PTCy prophylaxis regimen can reduce the incidence of aGVHD, decrease NRM and EBV-related complications, and achieve better OS compared to the ATG-based regimen. There was no significant difference between the two groups in cGVHD, RI, CMV reactivation, and BKV-related HC.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma

Qiang Zeng, Hang Zhang, Pu Kuang, Jian Li, Xinchuan Chen, Tian Dong, Qiuhui Wu, Chuanli Zhang, Chunping Chen, Ting Niu, Ting Liu, Zhigang Liu, Jie Ji

Summary: The conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan (ChiCGB) was effective in improving the prognosis of patients with peripheral T-cell (PTCL) or lymphoblastic T-cell lymphoma (T-LBL) undergoing autologous stem cell transplantation (ASCT). The regimen resulted in favorable overall survival and progression-free survival, with manageable adverse events. Randomized controlled trials are needed to further evaluate ChiCGB as a conditioning regimen for ASCT.

FRONTIERS IN ONCOLOGY (2023)

Article Hematology

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Yu Hu, Yan Li, Ying Cheng, Hai-Yan Yang, Jun-Ning Cao, Zun-Min Zhu, Jian-Da Hu, Wei Zhang, Hong-Mei Jing, Kai-Yang Ding, Xiang-Yang Zhang, Ren -Bin Zhao, Bin Zhang, Ya -Min Tian, Yong-Ping Song, Yu-Qin Song, Jun Zhu

Summary: Orelabrutinib demonstrates significant efficacy and tolerability in patients with relapsed or refractory mantle cell lymphoma, with a high overall response rate and median progression-free survival.

BLOOD ADVANCES (2023)

Article Hematology

Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study

Lijuan Deng, Zhiming Li, Huilai Zhang, Haiwen Huang, Jianda Hu, Lihong Liu, Ting Liu, Jie Jin, Zunmin Zhu, Wenyu Li, Zhenqian Huang, Wenrong Huang, Keshu Zhou, Haiyan Yang, Mingzhi Zhang, Kaiyang Ding, Hui Zhou, Yu Hu, Yuerong Shuang, Junning Cao, Sujun Gao, Dengju Li, Zimin Sun, Qingyuan Zhang, Shuhua Yi, Chunyan Ji, Liansheng Zhang, Cheng Hou, Yue Du, Weige Wang, Renbin Zhao, Yuqin Song, Jun Zhu

Summary: Orelabrutinib, a new-generation oral drug, demonstrated high response rates and good tolerability in patients with marginal zone lymphoma (MZL).

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Medicine, General & Internal

Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study

Xin-Xin Cao, Jie Jin, Cheng-Cheng Fu, Shu-Hua Yi, Wei-Li Zhao, Zi-Min Sun, Wei Yang, Deng-Ju Li, Guo-Hui Cui, Jian-da Hu, Ting Liu, Yong-Ping Song, Bing Xu, Zun-Min Zhu, Wei Xu, Ming-Zhi Zhang, Ya-Min Tian, Bin Zhang, Ren-Bin Zhao, Dao-Bin Zhou

Summary: Orelabrutinib has shown good efficacy and manageable safety profiles in patients with relapsed or refractory Waldenstrom's macroglobulinemia (R/R WM). The primary endpoint of this prospective study was to evaluate the major response rate (MRR) of orelabrutinib, which was found to be 80.9%, with an overall response rate of 89.4%.

ECLINICALMEDICINE (2022)

No Data Available